The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last projection. The U.S. is AstraZeneca’s largest market, generating 44% of its total revenue, according to its Q3 earnings presentation.

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease pipelines, the company said, with oncology seeing 22% growth. Cardiovascular, renal and metabolism (CVRM) experienced 21% growth, R&I 24% and rare disease 14%.

The boosted U.S. investment is said to be a response to Donald Trump’s election win, and leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in Liverpool.

AstraZeneca Plc raised its annual forecast, driven by strong demand for its blockbuster cancer drugs, and revealed a plan to invest $3.5 billion in the US business by the end of 2026.

AstraZeneca (NASDAQ:AZN) said it plans to spend $3.5B to expanding its research and manufacturing capabilities in the United States by the end of 2026. The U.K. drugmaker said the investment was part of its initiative to achieve $80B in total revenue by 2030.

AstraZeneca (GB:AZN) has released an update. AstraZeneca has announced a $3.5 billion investment in expanding its research and manufacturing